Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2023 Jul 28

PMID 37501682

Authors

Beom-Jun Kim

Ze-Yi Zheng

Jonathan T Lei

Matthew V Holt

Anran Chen

Jianheng Peng

Diana Fandino

Purba Singh

Hilda Kennedy

Yongchao Dou

Maria Del Rosario Chica-Parrado

Emmanuel Bikorimana

Dan Ye

Yunguan Wang

Ariella B Hanker

Nada Mohamed

Susan G Hilsenbeck

Bora Lim

Jaya Ruth Asirvatham

Arun Sreekumar

Bing Zhang

George Miles

Meenakshi Anurag

Matthew J Ellis

Eric C Chang

Affiliations

Soon will be listed here.

Abstract

Significance: A major challenge for targeting the consequence of tumor suppressor disruption is the accurate assessment of protein functional inactivation. NF1 can repress both RAS and ER signaling, and a ComboMATCH trial is underway to treat the patients with binimetinib and fulvestrant. Herein we report a MS-verified NF1 IHC assay that can determine a threshold for NF1 loss to predict treatment response. These approaches may be used to identify and expand the eligible patient population.

References

Yap Y, McPherson J, Ong C, Rozen S, Teh B, Lee A . The NF1 gene revisited - from bench to bedside. Oncotarget. 2014; 5(15):5873-92. PMC: 4171599. DOI: 10.18632/oncotarget.2194. View

Philpott C, Tovell H, Frayling I, Cooper D, Upadhyaya M . The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics. 2017; 11(1):13. PMC: 5480124. DOI: 10.1186/s40246-017-0109-3. View

Griffith O, Spies N, Anurag M, Griffith M, Luo J, Tu D . The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018; 9(1):3476. PMC: 6123466. DOI: 10.1038/s41467-018-05914-x. View

Medard G, Pachl F, Ruprecht B, Klaeger S, Heinzlmeir S, Helm D . Optimized chemical proteomics assay for kinase inhibitor profiling. J Proteome Res. 2015; 14(3):1574-86. DOI: 10.1021/pr5012608. View

Ellis M, Ding L, Shen D, Luo J, Suman V, Wallis J . Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486(7403):353-60. PMC: 3383766. DOI: 10.1038/nature11143. View

Duncan J, Whittle M, Nakamura K, Abell A, Midland A, Zawistowski J . Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012; 149(2):307-21. PMC: 3328787. DOI: 10.1016/j.cell.2012.02.053. View

Madanikia S, Bergner A, Ye X, Blakeley J . Increased risk of breast cancer in women with NF1. Am J Med Genet A. 2012; 158A(12):3056-60. PMC: 3507419. DOI: 10.1002/ajmg.a.35550. View

Zheng Z, Tian L, Bu W, Fan C, Gao X, Wang H . Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015; 12(3):511-24. PMC: 4512851. DOI: 10.1016/j.celrep.2015.06.044. View

Saltzman A, Leng M, Bhatt B, Singh P, Chan D, Dobrolecki L . gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data. Mol Cell Proteomics. 2018; 17(11):2270-2283. PMC: 6210220. DOI: 10.1074/mcp.TIR118.000850. View

10.

Martin J, Coverley J, Pattison S, BAXTER R . Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology. 1995; 136(3):1219-26. DOI: 10.1210/endo.136.3.7532580. View

11.

Anastasaki C, Le L, Kesterson R, Gutmann D . Updated nomenclature for human and mouse neurofibromatosis type 1 genes. Neurol Genet. 2017; 3(4):e169. PMC: 5530422. DOI: 10.1212/NXG.0000000000000169. View

12.

Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D . Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008; 10(12):1362-72, following 1372. PMC: 2586687. DOI: 10.1593/neo.08784. View

13.

Feng Q, OMalley B . Nuclear receptor modulation--role of coregulators in selective estrogen receptor modulator (SERM) actions. Steroids. 2014; 90:39-43. PMC: 4192004. DOI: 10.1016/j.steroids.2014.06.008. View

14.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

15.

Olson Jr J, Budd G, Carey L, Harris L, Esserman L, Fleming G . Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009; 208(5):906-14. PMC: 3683862. DOI: 10.1016/j.jamcollsurg.2009.01.035. View

16.

Gou X, Anurag M, Lei J, Kim B, Singh P, Seker S . Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021; 81(24):6259-6272. PMC: 9234971. DOI: 10.1158/0008-5472.CAN-21-1256. View

17.

Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M . CopywriteR: DNA copy number detection from off-target sequence data. Genome Biol. 2015; 16:49. PMC: 4396974. DOI: 10.1186/s13059-015-0617-1. View

18.

Saltzman A, Chan D, Holt M, Wang J, Jaehnig E, Anurag M . Kinase inhibitor pulldown assay (KiP) for clinical proteomics. Clin Proteomics. 2024; 21(1):3. PMC: 10790396. DOI: 10.1186/s12014-023-09448-3. View

19.

Li S, Shen D, Shao J, Crowder R, Liu W, Prat A . Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013; 4(6):1116-30. PMC: 3881975. DOI: 10.1016/j.celrep.2013.08.022. View

20.

Sherekar M, Han S, Ghirlando R, Messing S, Drew M, Rabara D . Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. J Biol Chem. 2019; 295(4):1105-1119. PMC: 6983858. DOI: 10.1074/jbc.RA119.010934. View